337 related articles for article (PubMed ID: 34226688)
1. Obstacles and opportunities in a forward vision for cancer nanomedicine.
de Lázaro I; Mooney DJ
Nat Mater; 2021 Nov; 20(11):1469-1479. PubMed ID: 34226688
[TBL] [Abstract][Full Text] [Related]
2. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
3. Evaluating Nanomedicines: Obstacles and Advancements.
Swierczewska M; Crist RM; McNeil SE
Methods Mol Biol; 2018; 1682():3-16. PubMed ID: 29039088
[TBL] [Abstract][Full Text] [Related]
4. DePEGylation strategies to increase cancer nanomedicine efficacy.
Kong L; Campbell F; Kros A
Nanoscale Horiz; 2019 Mar; 4(2):378-387. PubMed ID: 32254090
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficacy of nanomedicines for prostate cancer: An update.
Lakshmanan VK
Investig Clin Urol; 2016 Jan; 57(1):21-9. PubMed ID: 26966723
[TBL] [Abstract][Full Text] [Related]
6. Physiological determinants and plausible '6R' roadmap for clinical success of nanomedicines.
Shahiwala A
Nanomedicine (Lond); 2023 Aug; 18(18):1207-1222. PubMed ID: 37650539
[TBL] [Abstract][Full Text] [Related]
7. The Nano-Bio Interactions of Nanomedicines: Understanding the Biochemical Driving Forces and Redox Reactions.
Wang Y; Cai R; Chen C
Acc Chem Res; 2019 Jun; 52(6):1507-1518. PubMed ID: 31149804
[TBL] [Abstract][Full Text] [Related]
8. Antibody-Incorporated Nanomedicines for Cancer Therapy.
Wu SY; Wu FG; Chen X
Adv Mater; 2022 Jun; 34(24):e2109210. PubMed ID: 35142395
[TBL] [Abstract][Full Text] [Related]
9. Nanomedicines Targeting the Tumor Microenvironment.
Tong R; Langer R
Cancer J; 2015; 21(4):314-21. PubMed ID: 26222084
[TBL] [Abstract][Full Text] [Related]
10. Biological rationale for the design of polymeric anti-cancer nanomedicines.
Zhou Y; Kopeček J
J Drug Target; 2013 Jan; 21(1):1-26. PubMed ID: 23009337
[TBL] [Abstract][Full Text] [Related]
11. Engineering nanosystems to overcome barriers to cancer diagnosis and treatment.
Alhaj-Suliman SO; Wafa EI; Salem AK
Adv Drug Deliv Rev; 2022 Oct; 189():114482. PubMed ID: 35944587
[TBL] [Abstract][Full Text] [Related]
12. A Nanomedicine Structure-Activity Framework for Research, Development, and Regulation of Future Cancer Therapies.
Youden B; Jiang R; Carrier AJ; Servos MR; Zhang X
ACS Nano; 2022 Nov; 16(11):17497-17551. PubMed ID: 36322785
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in nano/micro systems for improved circulation stability, enhanced tumor targeting, penetration, and intracellular drug delivery: a review.
Chan WJ; Li H
Biomed Phys Eng Express; 2024 Jan; 10(2):. PubMed ID: 38086099
[TBL] [Abstract][Full Text] [Related]
14. Nanomedicines for cancer therapy: current status, challenges and future prospects.
Bor G; Mat Azmi ID; Yaghmur A
Ther Deliv; 2019 Feb; 10(2):113-132. PubMed ID: 30678550
[TBL] [Abstract][Full Text] [Related]
15. MSN anti-cancer nanomedicines: chemotherapy enhancement, overcoming of drug resistance, and metastasis inhibition.
He Q; Shi J
Adv Mater; 2014 Jan; 26(3):391-411. PubMed ID: 24142549
[TBL] [Abstract][Full Text] [Related]
16. Unlocking the Mitochondria for Nanomedicine-based Treatments: Overcoming Biological Barriers, Improving Designs, and Selecting Verification Techniques.
Pegoraro C; Domingo-Ortí I; Conejos-Sánchez I; Vicent MJ
Adv Drug Deliv Rev; 2024 Apr; 207():115195. PubMed ID: 38325562
[TBL] [Abstract][Full Text] [Related]
17. The spatiotemporal journey of nanomedicines in solid tumors on their therapeutic efficacy.
Qin M; Xia H; Xu W; Chen B; Wang Y
Adv Drug Deliv Rev; 2023 Dec; 203():115137. PubMed ID: 37949414
[TBL] [Abstract][Full Text] [Related]
18. Next-Generation Polymeric Nanomedicines for Oncology: Perspectives and Future Directions.
Fletcher NL; Kempe K; Thurecht KJ
Macromol Rapid Commun; 2020 Sep; 41(18):e2000319. PubMed ID: 32767396
[TBL] [Abstract][Full Text] [Related]
19. Nanomedicines as cancer therapeutics: current status.
Akhter S; Ahmad I; Ahmad MZ; Ramazani F; Singh A; Rahman Z; Ahmad FJ; Storm G; Kok RJ
Curr Cancer Drug Targets; 2013 May; 13(4):362-78. PubMed ID: 23517593
[TBL] [Abstract][Full Text] [Related]
20. Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders.
Muthu MS; Singh S
Nanomedicine (Lond); 2009 Jan; 4(1):105-18. PubMed ID: 19093899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
